Detalhe da pesquisa
1.
Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience.
Front Oncol;
12: 1026251, 2022.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36457484
2.
Rituximab-Containing Risk-Adapted Treatment Strategy in Nodular Lymphocyte Predominant Hodgkin Lymphoma: 7-Years Follow-Up.
Cancers (Basel);
13(8)2021 Apr 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33917062